Compare SWKH & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SWKH | VYGR |
|---|---|---|
| Founded | 1996 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Financial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 205.9M | 222.4M |
| IPO Year | 1999 | 2015 |
| Metric | SWKH | VYGR |
|---|---|---|
| Price | $17.25 | $3.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $18.00 | $17.00 |
| AVG Volume (30 Days) | 5.3K | ★ 745.6K |
| Earning Date | 03-18-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 120.89 | N/A |
| EPS | ★ 1.85 | N/A |
| Revenue | ★ $40,149,000.00 | $31,316,000.00 |
| Revenue This Year | $52.93 | N/A |
| Revenue Next Year | N/A | $71.77 |
| P/E Ratio | $9.31 | ★ N/A |
| Revenue Growth | ★ 62.38 | N/A |
| 52 Week Low | $13.17 | $2.65 |
| 52 Week High | $20.49 | $5.73 |
| Indicator | SWKH | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 38.11 |
| Support Level | N/A | $3.51 |
| Resistance Level | N/A | $4.09 |
| Average True Range (ATR) | 0.00 | 0.24 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 0.00 | 11.89 |
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.